Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Completed | Pancreatic Cancer | Biological, Drug, Drug, Drug, Other, Other, Procedure, Procedure, Procedure, Radiation - bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with combination chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: The phase II trial is studying the side effects and how well giving bevacizumab together with gemcitabine, oxaliplatin, fluorouracil, and radiation therapy works in treating patients undergoing surgery for locally advanced pancreatic cancer. | ||
|
Clinicaltrials.gov | Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery | Completed | Head and Neck Cancer | Drug, Genetic, Genetic, Other, Other, Other, Other, Procedure, Procedure - erlotinib hydrochloride, protein analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, neoadjuvant therapy, therapeutic conventional surgery | Wake Forest University Health Sciences, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Early Phase 1 | Interventional | RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery in treating patients with head and neck cancer that can be removed by surgery. | ||
|
Clinicaltrials.gov | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | Completed | Melanoma (Skin) | Biological, Other, Other, Other, Other, Procedure, Procedure, Procedure - sargramostim, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, cryosurgery, radiofrequency ablation | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Radiofrequency therapy and radiofrequency ablation use a high-frequency electric current to kill tumor cells. Radiofrequency therapy can also cause the body to produce heat-shock proteins which may help kill more tumor cells. Cryotherapy kills tumor cells by freezing them. It is not yet known whether heat-shock proteins caused by radiofrequency therapy given together with radiofrequency ablation or cryotherapy is more effective in treating stage IV melanoma than radiofrequency therapy-induced heat-shock proteins alone. PURPOSE: This randomized clinical trial is studying the side effects of radiofrequency therapy-induced endogenous heat-shock proteins when given alone or together with radiofrequency ablation or cryotherapy in treating patients with stage IV melanoma. | ||
|
Clinicaltrials.gov | DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements | Completed | Colorectal Cancer | Dietary Supplement, Genetic, Genetic, Genetic, Genetic, Genetic, Other, Other, Other, Procedure, Procedure - cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy | Roswell Park Cancer Institute, Other | 18 Years - 120 Years | N/A | Interventional | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying changes in DNA that affect vitamin D metabolism in patients with colorectal cancer receiving vitamin D supplements. | ||
Clinicaltrials.gov | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | Terminated | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | Drug, Other, Other, Other, Other - sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Bayer, Other, NIH, Industry | Female | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in at least the second remission. | |
|
Clinicaltrials.gov | Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | Completed | Head and Neck Cancer | Drug, Drug, Drug, Drug, Drug, Genetic, Genetic, Genetic, Genetic, Genetic, Other, Other, Procedure, Procedure, Radiation, Radiation - carboplatin, cisplatin, docetaxel, fluorouracil, lapatinib ditosylate, cytogenetic analysis, fluorescence in situ hybridization, in situ hybridization, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy, fludeoxyglucose F 18, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC, Other | 18 Years - 120 Years | Phase 1/Phase 2 | Interventional | RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with radiation therapy, with or without lapatinib, before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed or eliminate the need for surgery. PURPOSE: This phase I/II trial is studying the side effects and best dose of combination chemotherapy given together with radiation therapy with or without lapatinib and to see how well it works in treating patients with locally advanced cancer of the larynx or hypopharynx. | ||
|
Clinicaltrials.gov | Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy | Terminated | Brain and Central Nervous System Tumors, Thrombocytopenia | Drug, Genetic, Genetic, Other, Other, Radiation - temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood in the laboratory from patients receiving temozolomide may help doctors learn how temozolomide works in the body. It may also help doctors learn more about how a patient's genes may affect the risk of developing thrombocytopenia. PURPOSE: This clinical trial is studying the pharmacokinetics in patients with newly diagnosed high-grade glioma receiving temozolomide and radiation therapy. | |||
|
Clinicaltrials.gov | Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases | Biological, Drug, Genetic, Genetic, Other, Other, Procedure - sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving bexarotene together with GM-CSF may be an effective treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia. PURPOSE: This phase II trial is studying how well giving bexarotene together with GM-CSF works in treating patients with MDS or acute myeloid leukemia. | ||
|
Clinicaltrials.gov | Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200 | Completed | Colorectal Cancer | Genetic, Genetic, Genetic, Other - DNA methylation analysis, loss of heterozygosity analysis, microsatellite instability analysis, laboratory biomarker analysis | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tissue samples from patients with advanced colorectal cancer treated with fluorouracil and oxaliplatin with or without bevacizumab on clinical trial E-3200. | |||
|
Clinicaltrials.gov | Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | Completed | Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer | Other, Other, Other - immunologic technique, laboratory biomarker analysis, mass spectrometry | Wake Forest University Health Sciences, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in patients with kidney cancer or cancer of the urothelium and in healthy participants. | |||
|
Clinicaltrials.gov | Blood Samples From Patients on a Clinical Trial to CINV During HSCT | Terminated | Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor | Other, Other, Other - immunoenzyme technique, laboratory biomarker analysis, medical chart review | OHSU Knight Cancer Institute, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment. PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant. | |||
|
Clinicaltrials.gov | Identification of Biomarkers for Early Detection of Pancreatic Cancer | Completed | Pancreatic Cancer | Genetic, Other, Other, Other - protein expression analysis, laboratory biomarker analysis, mass spectrometry, surface-enhanced laser desorption/ionization-time of flight mass spectrometry | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer. | |||
|
Clinicaltrials.gov | Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy | Completed | Breast Cancer, Estrogen Receptor, Her-2, Pgr | Genetic, Genetic, Other, Other - microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict whether cancer will come back after treatment. PURPOSE: This laboratory study is identifying genes that may help predict recurrence in women with breast cancer treated with chemotherapy. | ||
|
Clinicaltrials.gov | Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer | Terminated | Breast Cancer | Drug, Drug, Other, Other, Other, Other, Procedure - dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, fluorescence imaging | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Observational | RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving tamoxifen for the prevention or treatment of breast cancer. | ||
|
Clinicaltrials.gov | Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer | Completed | Breast Cancer | Biological, Biological, Drug, Other, Other, Other, Other, Other, Procedure - allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Giving trastuzumab together with cyclophosphamide and vaccine therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving trastuzumab together with cyclophosphamide and vaccine therapy in treating patients with high-risk or metastatic breast cancer. | ||
|
Clinicaltrials.gov | Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow | Terminated | Breast Cancer | Drug, Other, Other, Other - sunitinib malate, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis | University of California, San Francisco, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with stage I, stage II, or stage III breast cancer who have tumor cells in the bone marrow. | ||
|
Clinicaltrials.gov | Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast | Completed | Breast Cancer | Drug, Genetic, Other, Other, Procedure, Procedure - vorinostat, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery | University of California, San Francisco, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast. | |
|
Clinicaltrials.gov | Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | Completed | Melanoma (Skin) | Biological, Other, Other, Other - B7-DC cross-linking antibody rHIgM12B7, flow cytometry, immunologic technique, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 1 | Interventional | RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a monoclonal antibody in treating patients with stage IV melanoma. | ||
|
Clinicaltrials.gov | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | Terminated | Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor | Other, Other, Other - flow cytometry, laboratory biomarker analysis, Data Collection | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH), Other, NIH, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease. PURPOSE: This clinical trial is studying T cells to see how well they help in predicting acute graft-versus-host disease in patients undergoing donor stem cell transplant. | |||
|
Clinicaltrials.gov | Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases | Terminated | Metastatic Cancer, Prostate Cancer | Drug, Other, Other, Procedure, Procedure - paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment | Wake Forest University Health Sciences, National Cancer Institute (NCI), Other, NIH | Male | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone. PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and bone metastases. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
